Evidence map›Paper›PMID 32678017›Full record

ArticleStem cell research & therapy2020

A synergistic role of convalescent plasma and mesenchymal stem cells in the treatment of severely ill COVID-19 patients: a clinical case report.

Hongbing Peng, Tiefeng Gong, Xiaoying Huang, Xun Sun, Hong Luo, Weizhong Wang, Junbiao Luo, Baowei Luo, Yanhui Chen, Xingxing Wang and 5 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell research & therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 8 pooled it
1.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 8 syntheses or guidelines pooled it, 62 citations in OpenAlex.

  1. Convalescent plasma for people with COVID-19: a living systematic review.The Cochrane database of systematic reviews · 2023
    Pooled it
  2. Convalescent plasma for people with COVID-19: a living systematic review.The Cochrane database of systematic reviews · 2023
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. SARS-CoV-2 Infection and Lung Regeneration.Clinical microbiology reviews · 2022
    Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 1 country.

Hongbing PengDepartment of Respiratory Medicine, Loudi Central Hospital, No. 51, Changqing Middle Street, Loudi, 417000, People's Republic of China. redcat8851@163.com.
Tiefeng GongDepartment of Respiratory Medicine, Loudi Central Hospital, No. 51, Changqing Middle Street, Loudi, 417000, People's Republic of China.
Xiaoying HuangDepartment of Respiratory Medicine, Loudi Central Hospital, No. 51, Changqing Middle Street, Loudi, 417000, People's Republic of China.
Xun SunInstitute of Reproductive and Stem Cell Engineering, School of Basic Medical Sciences, Central South University, 172 Tongzipo Road, Changsha, 410013, People's Republic of China.
Hong LuoDepartment of Respiratory and Critical Care Medicine, Second Xiangya Hospital, Central South University, No.139, Renmin Middle Road, Changsha, 410000, People's Republic of China.
Weizhong WangDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Nanhua University, No. 69 Chuanshan Road, Hengyang City, 421001, People's Republic of China.
Junbiao LuoDepartment of Critical Care Medicine, Second Affiliated Hospital of Nanhua University, No. 35 Jiefang Avenue, Xinxiang District, Hengyang City, 421001, People's Republic of China.
Baowei LuoDepartment of Respiratory Medicine, Loudi Central Hospital, No. 51, Changqing Middle Street, Loudi, 417000, People's Republic of China.
Yanhui ChenDepartment of Respiratory Medicine, Loudi Central Hospital, No. 51, Changqing Middle Street, Loudi, 417000, People's Republic of China.
Xingxing WangDepartment of Respiratory Medicine, Loudi Central Hospital, No. 51, Changqing Middle Street, Loudi, 417000, People's Republic of China.
Haifeng LongDepartment of Respiratory Medicine, Loudi Central Hospital, No. 51, Changqing Middle Street, Loudi, 417000, People's Republic of China.
Hua MeiNational Engineering Research Center of Human Stem Cells, Lugu High-tech Zone, Changsha, 410000, People's Republic of China.
Chuang LiNational Engineering Research Center of Human Stem Cells, Lugu High-tech Zone, Changsha, 410000, People's Republic of China.
Yanni DaiNational Engineering Research Center of Human Stem Cells, Lugu High-tech Zone, Changsha, 410000, People's Republic of China.
Honghui LiDepartment of Respiratory Medicine, Loudi Central Hospital, No. 51, Changqing Middle Street, Loudi, 417000, People's Republic of China.
Loudi Central Hospital · CNNational Engineering Research Center of Human Stem Cells · CNFirst Affiliated Hospital of University of South China · CNSecond Xiangya Hospital of Central South University · CNUniversity of South China · CN

Funding

Fund Project: Special Topic Project for Pneumonia Epidemic Infected by New Coronavirus in Loudi City 2020-Respiratory medicine-02Special Emergency Project for COVID-19 from Science and Technology Department of Hunan Province 2020SK3016
6 · The paper itself

Abstract

Acute respiratory distress syndrome virus-2 (SARS-CoV-2) responsible for coronavirus disease 2019 (COVID-19) infection, which causes global public health emergencies, has sped widely for more than 5 months and has the risk of long-term transmission. No effective treatment has been discovered to date. In the cases we report, the patient continued to deteriorate even after administration of antiviral drugs such as lopinavir/ritonavir, interferon-α, and ribavirin, as well as intravenous injection of meropenem, methylprednisolone, and immunoglobulin. So, we infused the patient with convalescent plasma (CP), and the absolute lymphocyte count increased the next day and returned to normal on the fourth day. Followed by intravenous infusion of mesenchymal stem cells (MSCs), bilateral infiltrates were absorbed and the pulmonary function was significantly improved. We note that the intravenous infusion of CP and MSCs for the treatment of severe COVID-19 patients may have synergistic characteristics in inhibiting cytokine storm, promoting the repair of lung injury, and recovering pulmonary function. We hope to provide a reference for the research direction of COVID-19 clinical strategies.

Indexed as

BetacoronavirusMesenchymal Stem Cell TransplantationAgedChinaCombined Modality TherapyCoronavirus InfectionsCOVID-19COVID-19 SerotherapyC-Reactive ProteinCytokinesFemaleHumansImmunization, PassiveLeukocyte CountLungNeutrophilsC-Reactive ProteinCytokinesConvalescent plasmaCoronavirus disease 2019COVID-19Mesenchymal stem cellsSARS-CoV-2

Identifiers

PMID32678017
PMCPMC7365301
OpenAlexW3043241086

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.